Siegfried Reich
Keine laufenden Positionen mehr
Profil
Siegfried Reich gründete eFFECTOR Therapeutics, Inc. Dr. Reich ist Chief Scientific Officer & Executive VP bei Turning Point Therapeutics, Inc. In der Vergangenheit war er Vice President bei Pfizer Inc. und Director & Head-Medicinal Chemistry bei Agouron Pharmaceuticals LLC (einer Tochtergesellschaft von Pfizer Inc.), Senior Vice President-Research bei eFFECTOR Therapeutics, Inc. und Vice President-Drug Discovery bei SGX Pharmaceuticals, Inc. Siegfried Reich erwarb einen Bachelor-Abschluss an der San Diego State University und einen Doktortitel an der University of California, Irvine.
Ehemalige bekannte Positionen von Siegfried Reich
Unternehmen | Position | Ende |
---|---|---|
TURG POIN | Chief Tech/Sci/R&D Officer | 04.03.2022 |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 18.04.2011 |
PFIZER, INC. | Corporate Officer/Principal | 01.12.2005 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Director/Board Member | 01.01.2001 |
EFFECTOR THERAPEUTICS, INC. | Founder | - |
Ausbildung von Siegfried Reich
San Diego State University | Undergraduate Degree |
University of California, Irvine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PFIZER, INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |